VJHemOnc is committed to improving our service to you

ASH 2019 | Melflufen in patients with refractory MM: updated analysis of HORIZON

VJHemOnc is committed to improving our service to you

Maria-Victoria Mateos

Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the updated analysis of the ongoing HORIZON study (NCT02963493) in patients with multiple myeloma (MM) refractory to pomalidomide and/or daratumumab, including a subgroup analysis of patients with triple-class refractory (no response or progression to at least one immunomodulatory imide drugs (IMiD), one proteasome inhibitor, and one anti-CD38 monoclonal antibody) and high-risk cytogenetics at baseline. Melflufen shows promising activity, including in subsets of patients with poor-risk features, including triple-class refractory and high-risk cytogenetics. Dr Mateos expects melflufen to be approved soon in order to be included in the treatment landscape of MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter